Neoadjuvant Carboplatin Boosts Targeted Therapy Responses in Triple-Negative Breast Cancer

The addition of neoadjuvant carboplatin to a regimen of taxane-anthracycline chemotherapy and targeted therapy substantially increased pathological complete responses in patients with stage II/III triple-negative breast cancer (but not in patients with HER2-positive disease), according to findings of the randomized phase II GeparSixto study conducted by the German Breast Group.